Cardiometabolic Diseases | Boehringer Ingelheim

Our growing portfolio of partnerships in Cardiovascular-Renal-Metabolic diseases spans the discovery and development value chain and includes partnerships with academia and industry including our long-standing, global strategic alliance with Eli Lilly and Company established in 2011. We are actively pursuing new early-science collaborations in our areas of partnering interest and look forward to expanding our community of innovation partners.

Our experience

Our innovation in Cardiovascular-Renal-Metabolic diseases is evidenced through our long history of excellence in research and landmark clinical trials, culminating in our most recent breakthrough treatments in type 2 diabetes, anticoagulation and heart failure care.

Our portfolio of marketed products includes treatments for:

Thromboembolic diseases
Type 2 diabetes
Acute myocardial infarction
Heart failure
Hypertension
Cardio-renal risk-reduction

Scientists in our research and development centers in Germany and the USA, are working with many academic and industry partners to discover and develop breakthrough treatments that continue our tradition of innovation excellence in Cardio-Renal-Metabolic disease research.

Our research focus

Our Cardiovascular-Renal-Metabolic disease research strategy takes a holistic view of the broader therapeutic needs of patients who may often have multiple conditions, connected by underlying similar pathologies. This approach allows us to take a broad perspective and explore a number of different research fields, allowing us to prioritize the most promising avenues of discovery and create synergies across our research programs.

Current research efforts focus on new strategies for the treatment of liver diseases, obesity and type 2 diabetes.

Our Partnering Interests

We are committed to discovering and developing the innovations of the future and are searching for differentiated novel products and new therapeutic concepts.

Our specific partnering interests offer various opportunities for collaboration on therapies that go beyond diabetes as we pursue the next wave of innovative medicines for Cardio-Renal-Metabolic diseases. While most of our partnering takes place between Discovery and Phase 1, we also consider exceptional opportunities in more advanced clinical stages.

Liver diseases: Metabolic dysfunction-associated steatohepatitis (MASH), liver fibrosis, cirrhosis, portal hypertension
Novel obesity treatments: Novel treatments achieving weight loss > 10%
Chronic kidney disease
CV specialty care and type 2 diabetes: Breakthrough treatment options